These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15584374)

  • 1. Testing efficacy of natural anxiolytic compounds.
    Roberts AA
    Adv Exp Med Biol; 2004; 546():181-91. PubMed ID: 15584374
    [No Abstract]   [Full Text] [Related]  

  • 2. Kava: a comprehensive review of efficacy, safety, and psychopharmacology.
    Sarris J; LaPorte E; Schweitzer I
    Aust N Z J Psychiatry; 2011 Jan; 45(1):27-35. PubMed ID: 21073405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanism of action, indications and abuse of benzodiazepine anxiolytic drugs].
    Goffinet S
    Ann Med Psychol (Paris); 1993 Jan; 151(1):47-63. PubMed ID: 7905724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neurobiological approach to anxiety].
    Boyer P
    Arch Mal Coeur Vaiss; 1987 May; 80 Spec No():43-6. PubMed ID: 2889436
    [No Abstract]   [Full Text] [Related]  

  • 5. Chrysin (5,7-dihydroxyflavone) exerts anxiolytic-like effects through GABA
    Rodríguez-Landa JF; Hernández-López F; Cueto-Escobedo J; Herrera-Huerta EV; Rivadeneyra-Domínguez E; Bernal-Morales B; Romero-Avendaño E
    Biomed Pharmacother; 2019 Jan; 109():2387-2395. PubMed ID: 30551498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Etifoxine: a new look at the GABA receptor and anxiety].
    Spadone C; Glikman M
    Encephale; 2008 Apr; 34 Spec No 1():1-11. PubMed ID: 18826172
    [No Abstract]   [Full Text] [Related]  

  • 7. Chlorogenic acid, a polyphenol from Prunus domestica (Mirabelle), with coupled anxiolytic and antioxidant effects.
    Bouayed J; Rammal H; Dicko A; Younos C; Soulimani R
    J Neurol Sci; 2007 Nov; 262(1-2):77-84. PubMed ID: 17698084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GABAA/benzodiazepine receptor: implications for the molecular basis of anxiety.
    Breier A; Paul SM
    J Psychiatr Res; 1990; 24 Suppl 2():91-104. PubMed ID: 1980704
    [No Abstract]   [Full Text] [Related]  

  • 9. The psychobiology of anxiolytic drugs. Part 1: Basic neurobiology.
    Sandford JJ; Argyropoulos SV; Nutt DJ
    Pharmacol Ther; 2000 Dec; 88(3):197-212. PubMed ID: 11337025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current hypotheses of the central mechanism of action of benzodiazepine tranquilizers].
    Bouchard LP; Llorca PM; Wolf MA
    Can J Psychiatry; 1991 Nov; 36(9):660-6. PubMed ID: 1685351
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of molecular substrate for the attenuation of anxiety: a step toward the development of better anti-anxiety drugs.
    Rudolph U
    ScientificWorldJournal; 2001 May; 1():192-3. PubMed ID: 12805666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the anxiolytic effects of chrysin, a Passiflora incarnata extract, in the laboratory rat.
    Brown E'; Hurd NS; McCall S; Ceremuga TE
    AANA J; 2007 Oct; 75(5):333-7. PubMed ID: 17966676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The aqueous crude extract of Montanoa frutescens produces anxiolytic-like effects similarly to diazepam in Wistar rats: involvement of GABAA receptor.
    Carro-Juárez M; Rodríguez-Landa JF; Rodríguez-Peña Mde L; Rovirosa-Hernández Mde J; García-Orduña F
    J Ethnopharmacol; 2012 Sep; 143(2):592-8. PubMed ID: 22885072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neural and molecular mechanisms in anxiety.
    Wolkowitz OM; Paul SM
    Psychiatr Clin North Am; 1985 Mar; 8(1):145-58. PubMed ID: 2859577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GABAA receptors as targets for novel anxiolytic drugs.
    Rupprecht R; Eser D; Zwanzger P; Möller HJ
    World J Biol Psychiatry; 2006; 7(4):231-7. PubMed ID: 17071543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A new group of anxiolytic drugs with a mechanism of action different from that of benzodiazepine derivatives].
    Kostowski W; Płaźnik A
    Pol Tyg Lek; 1988 Dec 19-26; 43(51-52):1647-9, 1683. PubMed ID: 2908340
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic potential of kava in the treatment of anxiety disorders.
    Singh YN; Singh NN
    CNS Drugs; 2002; 16(11):731-43. PubMed ID: 12383029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of selective anxiolytic compounds.
    Boulenger JP; Bisserbe JC
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():529A-530A. PubMed ID: 1354061
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical pharmacology of anxiolytic drugs: past, present and future.
    Lader M
    Adv Biochem Psychopharmacol; 1995; 48():135-52. PubMed ID: 7653323
    [No Abstract]   [Full Text] [Related]  

  • 20. Alpidem from pharmacology to clinic.
    Garreau M; Zivkovic B; Morselli PL
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():407A-408A. PubMed ID: 1354046
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.